Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Vickers, Andrew J ^a   Van Calster, Ben ^b,c   Steyerberg, Ewout W ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; BIOLOGICAL MARKER;

ANALYTIC METHOD; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CLINICAL DECISION MAKING; CONTROLLED STUDY; DATA ANALYSIS; DECISION ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HUMAN; NET BENEFIT ANALYSIS; PATIENT CODING; PREDICTION MODEL; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; DECISION SUPPORT SYSTEM; PREDICTIVE VALUE; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKERS; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 84959328652     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i6     Document Type: Article

References (14)

1. Steyerberg EW. A practical approach to development, validation, and updating. Clinical prediction models.Springer, 2009.
2. Ankerst DP, Hoefler J, Bock S et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 2014;83: 1362-7. doi:10.1016/j.urology.2014.02.035. 24862395
3. Liang Y, Ankerst DP, Ketchum NS et al. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol 2011;185: 104-10. doi:10.1016/j.juro.2010.08.088. 21074193
4. Vickers A, Cronin A, Roobol M et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28: 2493-8. doi:10.1200/JCO.2009.24.1968. 20421547
5. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26: 565-74. doi:10.1177/0272989X06295361. 17099194
6. Van Calster B, Vickers AJ. Calibration of risk prediction models: impact on decision-analytic performance. Med Decis Making 2015;35: 162-9. doi:10.1177/0272989X14547233. 25155798
7. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 2012;344: e4181. doi:10.1136/bmj.e4181 22723603
8. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008;8: 53. doi:10.1186/1472-6947-8-53. 19036144
9. Steyerberg EW, Vickers AJ. Decision curve analysis: a discussion. Med Decis Making 2008;28: 146-9. doi:10.1177/0272989X07312725. 18263565
10. Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat 2008;62: 314-20. doi:10.1198/000313008X370302. 19132141
11. Steyerberg EW, Vickers AJ, Cook NR et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21: 128-38. doi:10.1097/EDE.0b013e3181c30fb2. 20010215
12. Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest 2012;42: 216-28. doi:10.1111/j.1365-2362.2011.02562.x. 21726217
13. Van Calster B, Vickers AJ, Pencina MJ, Baker SG, Timmerman D, Steyerberg EW. Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. Med Decis Making 2013;33: 490-501. doi:10.1177/0272989X12470757. 23313931
14. Steyerberg EW, Moons KG, van der Windt DA et al. PROGRESS Group. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013;10: e1001381. doi:10.1371/journal.pmed.1001381. 23393430